Tropical calcific pancreatitis and fibrocalculus pancreatic diabetes in Bangladesh

The relationship between tropical calcific pancreatitis (TCP) and fibrocalculus pancreatic diabetes (FCPD) is still unclear. The clinical, biochemical and radiological data of age-matched TCP and FCPD subjects have been briefly discussed in the present review. Fibrocalculus pancreatic diabetes patients present with a significantly lower BMI compared with TCP patients. Analysis of the family history reveals that some kind of environmental factors seem to play a predominant role in the development of diabetes in FCPD patients, although these factors remain to be identified. Both TCP and FCPD patients predominantly come from a rural background. Fasting and 2 h blood glucose values as well as fructosamine levels in FCPD patients are approximately four-times higher than those of TCP patients. Measurements of early renal haemodynamic and microvascular changes (glomerular filtration rate, kidney size, microalbuminuria and microtransferrinuria) indicate an early renal involvement in FCPD patients. Tropical calcific pancreatitis subjects have approximately twice as high fasting C-peptide values compared with FCPD patients. Findings of single stranded DNA measurements suggest the involvement of oxidative damage in FCPD patients. Ketosis resistance is the most conspicuous clinical feature in the FCPD group and this relative absence of ketosis is probably due to a defect in the ketone body synthesis pathway and/or in the regulation of counterbalancing hormones. Endoscopic retrograde pancreatography findings of TCP and FCPD patients suggest that FCPD should not be considered only as a form of secondary diabetes consequent to generalized pancreatic damage in TCP.     

Pathology of shigellosis and its complications

One hundred and thirty-three colonic biopsies of proven cases of Shigella colitis were examined and post-mortem examinations were carried out on 29 fatal cases at the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B) hospital between 1988 and 1992. The distribution of pathological lesions and the spectrum of histopathological changes in the intestinal tract of these patients, and the features of intestinal and extra-intestinal complications of shigellosis are presented. Septicaemia, hyponatraemia, hypokalaemia and hypoglycaemia were present in a high percentage of these cases. All but two patients were malnourished at the time of autopsy. Shigellosis patients rapidly became hypoproteinaemic and were susceptible to other infections including opportunistic infections. Mortality amongst shigellosis patients admitted to our hospital continues to be high in spite of adequate antibiotic and supportive therapy.     

Targeted agents for the systemic treatment of advanced hepatocellular carcinoma

The prognosis for advanced hepatocellular carcinoma is poor and systemic therapy has historically been of limited benefit. However, novel targeted agents offer promise in improving patient outcomes. In a recent phase III study the oral multi-tyrosine kinase inhibitor sorafenib was demonstrated to have a survival advantage over a placebo in advanced hepatocellular carcinoma. Similar efficacy was demonstrated in a phase III trial limited to an Asian–Pacific group of patients. While these results are encouraging, it is vital to make further progress. In this review we examine current knowledge of targeted agents in advanced hepatocellular carcinoma. We also address some of the key issues that require exploration regarding the use of targeted agents in advanced hepatocellular carcinoma.     

Predicting the response to targeted therapy in metastatic colorectal cancer

Colorectal cancer is the second most common cause of cancer‐related deaths in Australia. The median survival of metastatic colorectal cancer remains poor, but novel targeted therapies offer promise in improving patient outcomes. However, it is vital to identify which patients with metastatic colorectal cancer will benefit from targeted therapy. Predictive biomarkers offer significant benefit by refining the treatment population to a subgroup that has a greater prospect of benefit from therapy. This provides efficacy benefits, but also minimizes the overall toxicity and cost of treatment. In this review we examine current knowledge regarding predictive biomarkers for targeted agents in metastatic colorectal cancer, with a particular focus on emerging biomarkers such as oncogenic mutations. We also highlight issues that require further exploration in the quest for personalized therapy in metastatic colorectal cancer.     

维生素D受体基因多态性与新疆南部地区维吾尔族儿童尿路结石相关性研究

目的：探讨维生素D受体（VDR）基因多态性与新疆南部地区维吾尔族儿童尿路结石相关性,阐明分子遗传学规律。方法：维吾尔族尿路结石患儿（病例组）74例和维吾尔族正常儿童（对照组）103例纳入此研究,应用聚合酶链反应-限制性片段长度多态性分析研究VDR基因FokI和ApaI位点多态性与新疆南部地区维吾尔族儿童尿路结石相关性。结果：VDR基因FokI位点FF、Ff、ff 3种基因型在病例组及对照组之间分布差异有统计学意义（χ2=7.818, P＜0.05）,基因型Ff在病例组占58%,明显高于对照组,差异有统计学意义（P＜0.05）。VDR基因ApaI位点AA、Aa、aa 3种基因型在病例组和对照组的分布差异无统计学差意义（P>0.05）。结论：VDR基因FokI位点多态性将来可作为维吾尔族儿童泌尿系结石的候选基因。     

Effect of treating lower urinary tract symptoms on anxiety, depression and psychiatric morbidity: A one-year study

BACKGROUND: The present study aimed to evaluate the effects of treating lower urinary tract symptoms (LUTS) on anxiety, depression and psychiatric morbidity following one year of follow-up. METHODS: A total of 297 patients were involved in this study. Patients were recruited into a surgical group (patients underwent transurethral resection of the prostate, n = 111), a medical group (underwent alpha-blockers treatment, n = 116) and a control group (renal stones patients with no or mild symptoms of severity, n = 70). Patients were assessed on anxiety, depression and psychiatric morbidity levels before and after treatment and were followed at 3, 6 and 12 months. RESULTS: The study showed that before treatment for LUTS, most of the patients, especially the surgical group compared to the medical and control groups, were more anxious, depressed and psychiatrically morbid. However, after treatment, most of the patients in the surgical group experienced a great improvement in their anxiety, depression and psychiatric morbidity level when compared to the medical and control groups. The reduction or improvement of their psychological profile was due to the reduction or total withdrawal of LUTS after treatment. CONCLUSION: Both medical and surgical treatment improved patient LUTS and thus improved their overall anxiety, depression and psychiatric morbidity.     

Construction of the Mandarin version of the International Prostate Symptom Score inventory in assessing lower urinary tract symptoms in a Malaysian population

BACKGROUND: The purpose of the present study was to validate the Mandarin version of the International Prostate Symptom Score (Mand-IPSS) in a Malaysian population. METHODS: The validity and reliability were studied in patients with lower urinary tract symptoms (LUTS; benign prostatic hyperplasia [BPH] group) and without LUTS (control group). Test-retest methodology was used to assess the reliability while Cronbach alpha was used to assess the internal consistency. Sensitivity to change was used to express the effect size index in the preintervention versus post-intervention score in patients with LUTS who underwent transurethral resection of the prostate. RESULTS: For the control group and BPH group, the internal consistency was excellent and a high degree of internal consistency was observed for all seven items (Cronbach alpha = 0.86-0.98 and 0.90-0.98, respectively). Test-retest correlation coefficients for all items were highly significant. Intraclass correlation coefficient (ICC) was high for the control (ICC = 0.93-0.99) and BPH group (ICC = 0.91-0.99). The sensitivity and specificity showed a high degree of sensitivity and specificity to the effects of treatment. A high degree of significance between baseline and post-treatment scores was observed across all seven items in the BPH group but not in the control group. CONCLUSIONS: The Mand-IPSS is a suitable, reliable, valid and sensitive instrument to measure clinical change in the Malaysian population.